Oncoceutics, Inc.

The Penn State Research Foundation

Other

Joshua E Allen

Martin Stogniew

Wafik S El-Deiry

Gen Sheng Wu

Gary Olson

Bhaskara Rao Nallaganchu

Richard S Pottorf

Varun Vijay Prabhu

Yanjun Sun

Gary L Olson

Bhaskara Nallaganchu

Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.

Imipridones for gliomas

Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.

G protein-coupled receptor (GPCR) modulation by imipridones

This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy

An adjustable integrated lug and drum mount composed of an integrated lug, a U-bracket and at least one mounting component, wherein the relative position of the mounting component with respect to the U-bracket is adjustable. The integrated lug and U-bracket are durably attached to the drum shell and one another with two fasteners. The U-bracket has a planar, free member, which connects with the mounting component(s). The planar, free member has one end, attached continuously to the bulk of the U-bracket, called the joined end. The planar, free member has another end, disposed distal to the joined end, called the free end, which can vibrate. The mounting components can be mounted substantially anywhere between the joined end and the free end. The adjustment changes the stiffness with which the integrated lug and drum mount connects the drum leg or support to the drum. The integrated lug has a threaded receiver that can accept a threaded shaft from a tuning screw.

Integrated lug and drum mount

7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

An adjustable drum mount composed of a fixed component and at least one mounting component, wherein the relative position of the mounting component with respect to the fixed component is adjustable. The fixed component is durably attached to the drum shell with fasteners. The fixed component has a planar, extending member, which connects with the mounting component(s). The planar, extending member has one end, attached continuously to the bulk of the fixed component, called the fixed end. The planar, extending member has another end, disposed distal to the fixed end, called the free end, which can vibrate. The mounting components can be mounted substantially anywhere between the fixed end and the free end. The adjustment changes the stiffness with which the drum mount connects the drum leg or support to the drum.

Drum mount

This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): (structurally represented) or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially. 

Growing community of inventors

New Haven, CT, United States of America

Joshua E Allen